A recent study shows that women with ovarian cancer who have the BRCA2 mutation live longer than those with the BRCA1 mutation. Because the BRCA1 and BRCA2 mutations works slightly differently, they have a different effect on survival. The BRCA2 mutation, according to research, keeps cancer cells from repairing after chemotherapy, which means that the beneficial effects last longer. This may also have implications for clinical trials, especially those exploring the use of PARP inhibitors.
Read more here